Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Macrophage blockade for the improvement of targeted radionuclide delivery to malignant tumours

Project description

Enhancing nanoparticle delivery by blocking macrophage uptake

Nanoparticles are engineered materials, small enough to travel through blood vessels and reach disease sites. For this reason, they have been used to carry medical drugs and imaging agents for diagnostics and therapy. However, accumulating evidence indicates that following administration most nanoparticles are cleared from blood vessels and taken up by macrophages in the liver and spleen. With the support of the Marie Skłodowska-Curie Actions programme, the RADBLOCK project aims to overcome this challenge and improve delivery of radioactive agents to tumours. Researchers propose a dual approach that involves nanoparticle modification with scaffold proteins that target HER2 receptors, found in aggressive breast and gastric cancers, and temporarily blocking the mononuclear phagocyte system.

Objective

The aim of RADBLOCK is to improve nanocarrier-based radionuclide delivery by enhancing targeting and overcoming problem of non-specific uptake of nanoparticles by macrophages in liver and spleen. For this purpose, two approaches will be used simultaneously: 1) modification of radionuclide-loaded nanoparticles with targeted scaffold proteins, recognizing HER2 receptor expressed by malignant cells; 2) temporal blockade of the cells of the mononuclear phagocyte system (MPS) to decrease elimination of the nanocarrier. The results of the project will be beneficial to the diagnostics and treatment of tumours with overexpression of HER2 receptors, such as human breast and gastric/gastroesophageal carcinomas. This project is novel and innovative, since presents first application of macrophage blockade technology for improving of radionuclide delivery with nanoparticles. RADBLOCK is a multidisciplinary project and combines modern chemical methods of nanocarrier preparation, physical methods for the material analysis and its comprehensive biological evaluation at the animals, bearing human xenografts. The applicant will conduct research in Uppsala University under supervision of Prof. Vladimir Tolmachev, expert in radiopharmaceutics and clinical applications of targeted scaffold proteins. As a two-way knowledge transfer fellow will be trained in methods of radiochemistry and radiopharmaceutics and will bring experience with nanomaterials chemistry and macrophage blockade techniques to the host organization. RADBLOCK is expected to increase radionuclide blood bioavailability in mammals and enhance specific tumour delivery, which will have positive effects on targeted diagnostics and therapy of malignant tumours with radionuclides.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

UPPSALA UNIVERSITET
Net EU contribution
€ 236 340,00
Address
VON KRAEMERS ALLE 4
751 05 Uppsala
Sweden
Region
Östra Sverige Östra Mellansverige Uppsala län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data